Back to Agenda
Session 7, Track C: Artificial Intelligence (AI) in Pharmacovigilance
Session Chair(s)
Vanessa Zapata
Associate Director, Regional Pharmacovigilance Officer
Merck Canada Inc., Canada
Nadia Mian, MS
Pharmacovigilance Manager
Ipsen Biopharmaceuticals Canada Inc., Canada
Agnes Jankowicz, MS
Vice President, Pharmacovigilance
Veristat, Canada
The use of Artificial Intelligence (AI) in pharmacovigilance has been increasing significantly. Companies have demonstrated how AI can be used for processing high volumes of Adverse Events to improve efficiencies without adding any ressources while reducing the risk of human errors.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize when AI can be used for a specific task
- Assess if a specific task would be performed more efficiently by AI than by a person
- Integrate AI to pharmacovigilance systems and workflows
Speaker(s)
Use of Digital Platform to Report Aes
Suzanne Tracy, MBA
Moderna, United States
Head, Digital Innovation, PV Operations
Use of Digital Platform to Report Aes
Farheen Shaikh, MS
Moderna , Canada
Director - Country Head, Pharmacovigilance, Canada
Predictive Modeling to Enhance Real-World Data for Safety Studies: Atopic Dermatitis as a Case Study
Heather Ward, PhD, MS
Pfizer, Canada
Director, Safety Surveillance Research
Have an account?